HC Wainwright Issues Positive Forecast for Oculis (NASDAQ:OCS) Stock Price

Key Points

• Oculis has had its price target raised by HC Wainwright from $32.00 to $33.00, indicating a potential upside of 85.39% from its current price.
• In addition, Chardan Capital also raised its price target for Oculis to $33.00, supporting a consensus "buy" rating among analysts.
• The company's lead product, OCS-01, is currently in Phase 3 clinical trials for treating diabetic macular edema, showcasing its focus on ophthalmic diseases.

Oculis (NASDAQ:OCS - Free Report) had its target price upped by HC Wainwright from $32.00 to $33.00 in a research note published on Friday morning,Benzinga reports. The firm currently has a buy rating on the stock.

Separately, Chardan Capital increased their price objective on Oculis from $28.00 to $33.00 and gave the stock a "buy" rating in a report on Friday, May 9th. Three research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the stock currently has a consensus rating of "Buy" and an average target price of $35.67.

Oculis Stock Up 0.3%

Oculis stock traded up $0.05 during trading hours on Friday, hitting $17.85. The company had a trading volume of 17,831 shares, compared to its average volume of 11,993. The firm has a market capitalization of $779.33 million, a P/E ratio of -6.69 and a beta of 0.27. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.55 and a quick ratio of 4.55. The firm's fifty day moving average is $18.38 and its 200-day moving average is $18.66. Oculis has a fifty-two week low of $11.56 and a fifty-two week high of $23.08.

Oculis (NASDAQ:OCS - Get Free Report) last released its quarterly earnings data on Thursday, August 21st. The company reported ($0.59) earnings per share for the quarter, missing the consensus estimate of ($0.53) by ($0.06). The company had revenue of $0.25 million during the quarter, compared to analyst estimates of $0.14 million. Oculis had a negative net margin of 13,958.12% and a negative return on equity of 90.31%. On average, research analysts forecast that Oculis will post -2.09 earnings per share for the current year.

Institutional Investors Weigh In On Oculis

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Bellevue Group AG acquired a new stake in Oculis during the fourth quarter worth $170,000. XTX Topco Ltd acquired a new position in Oculis in the fourth quarter valued at about $225,000. Kestra Private Wealth Services LLC acquired a new stake in Oculis during the 1st quarter worth $234,000. Geode Capital Management LLC raised its holdings in shares of Oculis by 12.0% during the fourth quarter. Geode Capital Management LLC now owns 16,744 shares of the company's stock worth $284,000 after acquiring an additional 1,800 shares during the period. Finally, Bosun Asset Management LLC acquired a new stake in shares of Oculis in the second quarter valued at approximately $378,000. 22.30% of the stock is owned by institutional investors and hedge funds.

Oculis Company Profile

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.